How well do rapid-acting insulins work in obese individuals?

Diabetes, Obesity and Metabolism

Volumn 8, Issue 4, 2006, Pages 388-395

  Barnett, Anthony H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Obesity; Rapid actinginsulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; RAPID ACTING INSULIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BODY FAT; BODY MASS; BODY WEIGHT DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; EDEMA; FEEDING BEHAVIOR; FLUID RETENTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHARMACODYNAMICS; POSTPRANDIAL STATE; REVIEW; SKINFOLD THICKNESS; SUBCUTANEOUS FAT;

EID: 33748468360     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00525.x     Document Type: Review

References (53)

1. Owens D, Zinman B, Bolli G. Insulins today and beyond. Lancet 2001; 358: 739-746.
2. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
3. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). (UK Prospective Diabetes Study Group). Lancet 1998; 352: 837-853.
4. ADA. Diagnosis and classification of diabetes mellitus Diabetes Care 2004; 27: S5-S10.
5. Albu J, Pi-Sunyer FX. Obesity and diabetes. In: Bray G, Bouchard C, James W, eds. Handbook of Diabetes. New York: Marcel Dekker, 1998; 697-707.
6. Rosenstock J. Insulin therapy: Optimizing control in type 1 and type 2 diabetes. Clin Cornerstone 2001; 4: 50-64.
7. White JR Jr, Campbell RK. Insulin in the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm 2003; 60: 1145-1152.
8. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
9. Finegood DT, McArthur MD, Kojwang D et al. β-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
10. Rosenstock J, Riddle M. Chapter 9: Insulin therapy in type 2 diabetes. In: Cefalu W, Gerich J, LeRoith D, eds. The CADRE Handbook of Diabetes Management. New York: Medical Information Press, 2004; 145-168.
11. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
12. Rosenstock J. Chapter 24: Insulin strategies in type 2 diabetes. URL: http://www.endotext.com, 2003. Accessed April 2005.
13. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805-822.
14. Bloomgarden ZT. American association of clinical endocrinologists meeting, May 2002. Diabetes Care 2002; 25: 1464-1471.
15. Controlling the global obesity epidemic. World Health Organization, 2003.
16. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6: 97-106.
17. Zimmet PZ, McCarty DJ, de Courten MP. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997; 11: 60-68.
18. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology -from West to the rest. Diabetes Care 1992; 15: 232-252.
19. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050-1064.
20. Dowse GK, Zimmet PZ, Gareeboo H et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 1991; 14: 271-282.
21. Rosenstock J, Wyne K. Insulin treatment in type 2 diabetes. In: Goldstein B, Müller-Wieland D, eds. Textbook of Type 2 Diabetes. London: Martin Dunitz, 2003; 131-154.
22. Bethel MA, Feinglos MN. Insulin analogues: New therapies for type 2 diabetes mellitus. Curr Diab Rep 2002; 2: 403-408.
23. White JR Jr, Campbell RK, Hirsch I. Insulin analogues: New agents for improving glycemic control. Postgrad Med 1997; 101: 58-60, 63 -65, 70.
24. Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001; 54: 105-114.
25. DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med 2003; 20: 312-318.
26. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2000; 17: 762-770.
27. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588.
28. Schernthaner G, Wein W, Shnawa N, Bates PC, Birkett MA. Preprandial vs. postprandial insulin lispro -a comparative crossover trial in patients with Type 1 diabetes. Diabet Med 2004; 21: 279-284.
29. Anderson JH Jr, Brunelle RL, Keohane P et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157: 1249-1255.
30. Anderson JH Jr, Brunelle RL, Koivisto VA et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265-270.
31. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther 1997; 19: 62-72.
32. Rosenfalck A, Thorsby P, Kjems L et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37: 41-46.
33. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: A randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 2000; 23: 1232-1235.
34. Czock D, Aisenpreis U, Rasche FM, Jehle PM. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther 2003; 41: 492-497.
35. Heller S, Amiel S, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycaemia during intensified insulin therapy. Diabetes Care 1999; 22: 1607-1611.
36. Ahmed AB, Home PD. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diabetes Care 1998; 21: 1707-1713.
37. Lalli C, Ciofetta M, Del Sindaco P et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-477.
38. Garg S, Andersen J, Gerard L. Impact of insulin lispro on HbA1c values in insulin pump users. Diabetes Obesity Metab 2000; 2: 307-311.
39. Ciofetta M, Lalli C, Del Sindaco P et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-800.
40. Fairchild JM, Ambler GR, Genoud-Lawton CH et al. Insulin lispro versus regular insulin in children with type 1 diabetes on twice daily insulin. Pediatr Diabetes 2000; 1: 135-141.
41. Jehle PM, Fussganger RD, Seibold A, Luttke B, Bohm BO. Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. Int J Clin Pharmacol Ther 1996; 34: 498-503.
42. Paquot N, Roulin D, Schneiter P et al. Effects of regular insulin or insulin LISPRO on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus. Diabetes Metab 1998; 24: 523-558.
43. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care 1995; 18: 986-991.
44. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh) 1969; 2: 1-84.
45. Frid A, Linde B. Intraregional differences in the absorption of unmodified insulin from the abdominal wall. Diabet Med 1992; 9: 236-239.
46. Frick A, Becker R, Wessels D, Scholtz H. Pharmacokinetic and glucodynamic profiles of insulin glulisine: An evaluation following subcutaneous administration at various injection sites. Diabetologia 2003; 46: 776 [Abstract].
47. Becker R, Frick A, Wessels D, Scholtz H. Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine - a novel, rapid-acting, human insulin analogue. Diabetologia 2003; 46: 775 [Abstract].
48. Frick A, Burger F, Scholz H, Becker R. Time-action profile of insulin glulisine versus regular human insulin and insulin lispro in obese subjects. Diabetes 2004; 52: A124 [Abstract 526-P].
49. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981; 70: 579-588.
50. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
51. ter Braak EW, Woodworth JR, Bianchi R et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. diabetes Care 1996; 19: 1437-1440.
52. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 (Suppl. 2): B109-B113.
53. Barnett AH, Capaldi B, Davies-Lyons M et al. Expert opinion statement on the use of insulin therapy in patients with type 2 diabetes in primary care. Pract Diab Int 2003; 20: 97-102.